Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

8.22USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$8.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
337,937
52-wk High
$9.11
52-wk Low
$4.61

Chart for

About

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging... (more)

Overall

Beta: 3.54
Market Cap(Mil.): $515.08
Shares Outstanding(Mil.): 70.27
Dividend: --
Yield (%): --

Financials

  PGNX.OQ Industry Sector
P/E (TTM): -- 85.48 32.76
EPS (TTM): -0.06 -- --
ROI: -3.04 2.29 14.61
ROE: -5.26 3.86 16.34

BRIEF-Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating To Patent Infringement

* PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT

May 11 2018

BRIEF-Progenics Pharmaceuticals Announces Q1 Loss Per Share $0.19

* PROGENICS PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

May 09 2018

BRIEF-Progenics Says FDA Will Extend Review Of NDA For Azedra By Three Months

* PROGENICS PHARMACEUTICALS ANNOUNCES THREE-MONTH EXTENSION OF PDUFA DATE FOR AZEDRA (IOBENGUANE I 131)

Mar 22 2018

Earnings vs. Estimates